Kyoto University professor Shinya Yamanaka, left, and Takeda Pharmaceutical President Christophe Weber after their news conference in Tokyo on Feb. 3. (Photo by Nanami Sato)
TAITO KUROSE, HINAKO BANNO and YASUKI OKAMOTO
February 4, 2026 01:12 JST
TOKYO/OSAKA — Japan’s Takeda Pharmaceutical and Kyoto University are ending a 10-year research project on induced pluripotent stem (iPS) cells at the end of fiscal 2025, having developed talent and foundational technologies but no new drugs that reached practical use.
AloJapan.com